Publication date: Jul 03, 2026
S-268024 is a recombinant protein vaccine developed as a COVID-19 booster. This randomized, observer-blind, phase 3 study enrolled previously vaccinated Japanese adults without a history of SARS-CoV-2 infection. The noninferiority of the immunogenicity of the S-268024 booster vaccination versus NVX-CoV2373 was assessed. The immunogenicity population included 733 (S-268024 group: n = 368; NVX-CoV2373 group: n = 365) of 734 randomized participants. The geometric mean titer (GMT) ratio (95% confidence interval [CI]) was 1. 79 (1. 52-2. 12), and the difference in seroresponse rate (95% CI) of SARS-CoV-2 neutralizing antibody was 7. 9% (1. 3%-14. 4%) on day 29. The lower limit of 95% CI exceeded prespecified margins, indicating noninferior immunogenicity of S-268024 versus NVX-CoV2373; superiority in GMT was also demonstrated. Treatment-related adverse events (AEs) were numerically higher with S-268024 (92. 4%) than NVX-CoV2373 (77. 5%), with no treatment-related deaths/serious AEs/AEs of special interest. Interim analyses established noninferiority and superiority of S-268024 to NVX-CoV2373 in immunogenicity, with an acceptable safety profile.
Open Access PDF
| Concepts | Keywords |
|---|---|
| Blind | |
| Japanese | |
| Recombinant | |
| Vaccine |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | COVID-19 |
| pathway | REACTOME | SARS-CoV-2 Infection |
| disease | MESH | included |